How Ph.D. was paid
$8.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Raymond Stevens, Ph.D.Chief Executive Officer and Director | $672,094 | $2,387,996 | $4,846,926 | $508,871 | $14,000 | $8,429,887 |
| Jun YoonChief Financial Officer | $530,530 | $1,193,998 | $2,423,463 | $309,075 | $10,529 | $4,467,595 |
| Blai Coll, M.D., Ph.D.Chief Medical Officer | $492,813 | $820,866 | $1,666,117 | $253,151 | $14,000 | $3,246,947 |
| Xichen Lin, Ph.D.Chief Scientific Officer | $505,313 | $567,150 | $1,151,143 | $257,103 | — | $2,480,709 |
| Yingli Ma, Ph.D.Chief Technology Officer | $429,768 | $447,734 | $908,788 | $212,592 | — | $1,998,882 |
What changed and why
- 93%Approximately 93% of our Chief Executive Officer's target total direct compensation was considered variable and at-risk.
- 6%For 2025, our Board modestly increased our Chief Executive Officer's base salary by 6%.
- 125%Our Board determined that we achieved 2025 corporate performance of 125% of target.
- 125%2025 annual bonuses were paid to our Chief Executive Officer at 125% of target.
- 67%The target mix of annual equity awards granted to each NEO was approximately 67% options and 33% RSUs.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.